IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Kachroo, Puja ^a,b   Lee, Mi Heon ^a   Zhang, Ling ^a   Baratelli, Felicita ^a,b   Lee, Gina ^a,b   Srivastava, Minu K ^a,c   Wang, Gerald ^a,b   Walser, Tonya C ^a,b   Krysan, Kostyantyn ^a,b   Sharma, Sherven ^a,c   Dubinett, Steven M ^a,b,c   Lee, Jay M ^a,b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Department of Medicine   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d UCLA MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Cytokine; Epithelial mesenchymal transition; IL 27; STAT1; STAT3

Indexed keywords

EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; INTERLEUKIN 8; JANUS KINASE; NERVE CELL ADHESION MOLECULE; PLAKOGLOBIN; RECOMBINANT INTERLEUKIN 27; SMALL INTERFERING RNA; STAT1 PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN; VASCULOTROPIN; VIMENTIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ASSAY; CELL MIGRATION; CELL MOTILITY; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; LUNG SMALL CELL CANCER; MESENCHYME; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION REGULATION; TUMOR CELL LINE; WESTERN BLOTTING;

ANGIOGENIC PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; INTERLEUKIN-27; LUNG NEOPLASMS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TRANSFECTION;

EID: 84888091506     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-97     Document Type: Article

References (68)

1. Understanding the pro- and anti-inflammatory properties of IL-27. Villarino AV, Huang E, Hunter CA, J Immunol 2004 173 2 715 720 15240655 (Pubitemid 38924243)
2. IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. Salcedo R, Stauffer JK, Lincoln E, Back TC, Hixon JA, Hahn C, Shafer-Weaver K, Malyguine A, Kastelein R, Wigginton JM, J Immunol 2004 173 12 7170 7182 15585838 (Pubitemid 39628152)
3. Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Cocco C, Giuliani N, Di Carlo E, Ognio E, Storti P, Abeltino M, Sorrentino C, Ponzoni M, Ribatti D, Airoldi I, Clin Cancer Res 2010 16 16 4188 4197 10.1158/1078-0432.CCR-10-0173 20587591
4. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Chiyo M, Shimozato O, Yu L, Kawamura K, Iizasa T, Fujisawa T, Tagawa M, Int J Cancer 2005 115 3 437 442 10.1002/ijc.20848 15688376 (Pubitemid 40663748)
5. Antiangiogenic and antitumor activities of IL-27. Shimizu M, Shimamura M, Owaki T, Asakawa M, Fujita K, Kudo M, Iwakura Y, Takeda Y, Luster AD, Mizuguchi J, et al. J Immunol 2006 176 12 7317 7324 16751375 (Pubitemid 43849032)
6. Potent antitumor activity of interleukin-27. Hisada M, Kamiya S, Fujita K, Belladonna ML, Aoki T, Koyanagi Y, Mizuguchi J, Yoshimoto T, Cancer Res 2004 64 3 1152 1156 10.1158/0008-5472.CAN-03-2084 14871851 (Pubitemid 38176923)
7. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Oniki S, Nagai H, Horikawa T, Furukawa J, Belladonna ML, Yoshimoto T, Hara I, Nishigori C, Cancer Res 2006 66 12 6395 6404 10.1158/0008-5472.CAN-05-4087 16778218
8. Antiproliferative activity of IL-27 on melanoma. Yoshimoto T, Morishima N, Mizoguchi I, Shimizu M, Nagai H, Oniki S, Oka M, Nishigori C, Mizuguchi J, J Immunol 2008 180 10 6527 6535 18453571
9. Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Hurteau JA, Blessing JA, DeCesare SL, Creasman WT, Gynecol Oncol 2001 82 1 7 10 11426954 (Pubitemid 32634946)
10. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. Motzer RJ, Rakhit A, Thompson JA, Nemunaitis J, Murphy BA, Ellerhorst J, Schwartz LH, Berg WJ, Bukowski RM, J Interferon Cytokine Res 2001 21 4 257 263 10.1089/107999001750169934 11359657 (Pubitemid 32680910)
11. STATs and gene regulation. Darnell JE Jr, Science 1997 277 5332 1630 1635 10.1126/science.277.5332.1630 9287210 (Pubitemid 27446219)
12. STAT-1: a novel regulator of apoptosis. Stephanou A, Latchman DS, Int J Exp Pathol 2003 84 6 239 244 14748743 (Pubitemid 38221802)
13. Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Huang M, Page C, Reynolds RK, Lin J, Gynecol Oncol 2000 79 1 67 73 10.1006/gyno.2000.5931 11006034
14. Stat3 as an oncogene. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr, Cell 1999 98 3 295 303 10.1016/S0092-8674(00)81959-5 10458605 (Pubitemid 29380565)
15. STAT3: a multifaceted oncogene. Levy DE, Inghirami G, Proc Natl Acad Sci USA 2006 103 27 10151 10152 10.1073/pnas.0604042103 16801534 (Pubitemid 44051135)
16. Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Huang S, Bucana CD, Van Arsdall M, Fidler IJ, Oncogene 2002 21 16 2504 2512 10.1038/sj.onc.1205341 11971185 (Pubitemid 34438103)
17. STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer. Deng JY, Sun D, Liu XY, Pan Y, Liang H, World J Gastroenterol 2010 16 42 5380 5387 10.3748/wjg.v16.i42.5380 21072904
18. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al. Oncogene 2002 21 13 2000 2008 10.1038/sj.onc.1205260 11960372 (Pubitemid 34270888)
19. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M, J Urol 2002 168 2 762 765 10.1016/S0022-5347(05)64741-6 12131365 (Pubitemid 34793359)
20. Activation of STAT3 in thymic epithelial tumours correlates with tumour type and clinical behaviour. Chang KC, Wu MH, Jones D, Chen FF, Tseng YL, J Pathol 2006 210 2 224 233 10.1002/path.2041 16917804 (Pubitemid 44463937)
21. Prognostic significance of STAT3 and phosphorylated STAT3 in human soft tissue tumors-a clinicopathological analysis. David D, Rajappan LM, Balachandran K, Thulaseedharan JV, Nair AS, Pillai RM, J Exp Clin Cancer Res 2011 30 56 10.1186/1756-9966-30-56 21575192
22. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Hunter CA, Nat Rev Immunol 2005 5 7 521 531 10.1038/nri1648 15999093 (Pubitemid 40961330)
23. Jaks and STATs: biological implications. Leonard WJ, O'Shea JJ, Annu Rev Immunol 1998 16 293 322 10.1146/annurev.immunol.16.1.293 9597132 (Pubitemid 28183367)
24. The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Hay ED, Dev Dyn 2005 233 3 706 720 10.1002/dvdy.20345 15937929 (Pubitemid 40853448)
25. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW, J Cell Physiol 2007 213 2 374 383 10.1002/jcp.21223 17680632 (Pubitemid 47509716)
26. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Lee TK, Poon RT, Yuen AP, Ling MT, Kwok WK, Wang XH, Wong YC, Guan XY, Man K, Chau KL, et al. Clin Cancer Res 2006 12 18 5369 5376 10.1158/1078-0432.CCR-05-2722 17000670 (Pubitemid 44497250)
27. IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities. Ho MY, Leu SJ, Sun GH, Tao MH, Tang SJ, Sun KH, J Immunol 2009 183 10 6217 6226 10.4049/jimmunol.0901272 19841177
28. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al. Nature 2013 499 7457 214 218 10.1038/nature12213 23770567
29. IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled. Reddy EP, Korapati A, Chaturvedi P, Rane S, Oncogene 2000 19 21 2532 2547 10.1038/sj.onc.1203594 10851052 (Pubitemid 30339209)
30. Acquiring signalling specificity from the cytokine receptor gp130. Ernst M, Jenkins BJ, Trends Genet 2004 20 1 23 32 10.1016/j.tig.2003.11.003 14698616 (Pubitemid 38032817)
31. Liposome-based DNA carriers may induce cellular stress response and change gene expression pattern in transfected cells. Fiszer-Kierzkowska A, Vydra N, Wysocka-Wycisk A, Kronekova Z, Jarzab M, Lisowska KM, Krawczyk Z, BMC Mol Biol 2011 12 27 10.1186/1471-2199-12-27 21663599
32. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Song L, Turkson J, Karras JG, Jove R, Haura EB, Oncogene 2003 22 27 4150 4165 10.1038/sj.onc.1206479 12833138 (Pubitemid 36876236)
33. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Schust J, Sperl B, Hollis A, Mayer TU, Berg T, Chem Biol 2006 13 11 1235 1242 10.1016/j.chembiol.2006.09.018 17114005 (Pubitemid 44750735)
34. The basics of epithelial-mesenchymal transition. Kalluri R, Weinberg RA, J Clin Invest 2009 119 6 1420 1428 10.1172/JCI39104 19487818
35. Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Strutz F, Zeisberg M, Ziyadeh FN, Yang CQ, Kalluri R, Muller GA, Neilson EG, Kidney Int 2002 61 5 1714 1728 10.1046/j.1523-1755.2002.00333.x 11967021 (Pubitemid 34437925)
36. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA, Nat Cell Biol 2000 2 2 76 83 10.1038/35000025 10655586
37. Tumor metastasis: a new twist on epithelial-mesenchymal transitions. Vernon AE, LaBonne C, Curr Biol 2004 14 17 719 R721 10.1016/j.cub.2004.08.048 15341765 (Pubitemid 39290047)
38. Epithelial-mesenchymal transitions in development and pathologies. Thiery JP, Curr Opin Cell Biol 2003 15 6 740 746 10.1016/j.ceb.2003.10.006 14644200 (Pubitemid 37487967)
39. Angiogenesis in cancer and other diseases. Carmeliet P, Jain RK, Nature 2000 407 6801 249 257 10.1038/35025220 11001068
40. Role of angiogenesis in tumor growth and metastasis. Folkman J, Semin Oncol 2002 29 6 Suppl 16 15 18
41. Molecular basis of angiogenesis and cancer. Tonini T, Rossi F, Claudio PP, Oncogene 2003 22 42 6549 6556 10.1038/sj.onc.1206816 14528279 (Pubitemid 37372334)
42. Vascular-specific growth factors and blood vessel formation. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J, Nature 2000 407 6801 242 248 10.1038/35025215 11001067
43. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, Strieter RM, J Clin Invest 1996 97 12 2792 2802 10.1172/JCI118734 8675690 (Pubitemid 26197092)
44. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Morris SB, Xue YY, Burdick MD, Glass MC, Iannettoni MD, Strieter RM, J Clin Invest 1998 102 3 465 472 10.1172/JCI3145 9691082 (Pubitemid 28376148)
45. Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis. Battle TE, Lynch RA, Frank DA, Cancer Res 2006 66 7 3649 3657 10.1158/0008-5472.CAN-05-3612 16585190
46. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, Oberg K, Wiedenmann B, Hocker M, Rosewicz S, J Natl Cancer Inst 2003 95 6 437 448 10.1093/jnci/95.6.437 12644537 (Pubitemid 36432418)
47. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS, Gallick GE, Oncogene 2005 24 19 3110 3120 10.1038/sj.onc.1208513 15735682 (Pubitemid 40695080)
48. IFN-beta-mediated inhibition of IL-8 expression requires the ISGF3 components Stat1, Stat2, and IRF-9. Laver T, Nozell SE, Benveniste EN, J Interferon Cytokine Res 2008 28 1 13 23 10.1089/jir.2007.0062 18370868 (Pubitemid 351171384)
49. Signal transducer and activator of transcription 3 upregulates interleukin-8 expression at the level of transcription in human melanoma cells. Oka M, Sakaguchi M, Okada T, Nagai H, Ozaki M, Yoshioka T, Inoue H, Mukaida N, Kikkawa U, Nishigori C, Exp Dermatol 2010 19 8 50 e55 19758315
50. The crossroads of oncogenesis and metastasis. Sanchez-Garcia I, N Engl J Med 2009 360 3 297 299 10.1056/NEJMcibr0808031 19144947
51. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Dohadwala M, Yang SC, Luo J, Sharma S, Batra RK, Huang M, Lin Y, Goodglick L, Krysan K, Fishbein MC, et al. Cancer Res 2006 66 10 5338 5345 10.1158/0008-5472.CAN-05-3635 16707460 (Pubitemid 43844959)
52. Stat5a is mandatory for adult mammary gland development and lactogenesis. Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L, Genes Dev 1997 11 2 179 186 10.1101/gad.11.2.179 9009201 (Pubitemid 27081895)
53. STAT1 is required for redifferentiation during Madin-Darby canine kidney tubulogenesis. Kim M, O'Brien LE, Kwon SH, Mostov KE, Mol Biol Cell 2010 21 22 3926 3933 10.1091/mbc.E10-02-0112 20861313
54. Emerging evidence of epithelial-to-mesenchymal transition in lung carcinogenesis. Sato M, Shames DS, Hasegawa Y, Respirology 2012 17 7 1048 1059 10.1111/j.1440-1843.2012.02173.x 22452538
55. Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K, Clin Cancer Res 2000 6 12 4789 4796 11156236 (Pubitemid 32110421)
56. Reduced expression of alpha-catenin, beta-catenin, and gamma-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer. Pirinen RT, Hirvikoski P, Johansson RT, Hollmen S, Kosma VM, J Clin Pathol 2001 54 5 391 395 10.1136/jcp.54.5.391 11328840 (Pubitemid 32458139)
57. Epithelial-mesenchymal transition in cancer development and its clinical significance. Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, Baba H, Mori M, Cancer Sci 2010 101 2 293 299 10.1111/j.1349-7006.2009.01419.x 19961486
58. Vimentin in cancer and its potential as a molecular target for cancer therapy. Satelli A, Li S, Cell Mol Life Sci 2011 68 18 3033 3046 10.1007/s00018-011-0735-1 21637948
59. Biologic consequences of Stat1-independent IFN signaling. Gil MP, Bohn E, O'Guin AK, Ramana CV, Levine B, Stark GR, Virgin HW, Schreiber RD, Proc Natl Acad Sci USA 2001 98 12 6680 6685 10.1073/pnas.111163898 11390995 (Pubitemid 32538276)
60. Alternative activation of STAT1 and STAT3 in response to interferon-gamma. Qing Y, Stark GR, J Biol Chem 2004 279 40 41679 41685 10.1074/jbc.M406413200 15284232 (Pubitemid 39313613)
61. Stat1-independent regulation of gene expression in response to IFN-gamma. Ramana CV, Gil MP, Han Y, Ransohoff RM, Schreiber RD, Stark GR, Proc Natl Acad Sci USA 2001 98 12 6674 6679 10.1073/pnas.111164198 11390994 (Pubitemid 32538275)
62. Of JAKs, STATs, blind watchmakers, jeeps and trains. Kerr IM, Costa-Pereira AP, Lillemeier BF, Strobl B, FEBS Lett 2003 546 1 1 5 10.1016/S0014-5793(03)00411-3 12829228 (Pubitemid 36782275)
63. Jaks and Stats in signaling by the cytokine receptor superfamily. Ihle JN, Kerr IM, Trends Genet 1995 11 2 69 74 10.1016/S0168-9525(00)89000-9 7716810
64. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. Sano S, Itami S, Takeda K, Tarutani M, Yamaguchi Y, Miura H, Yoshikawa K, Akira S, Takeda J, EMBO J 1999 18 17 4657 4668 10.1093/emboj/18.17.4657 10469645 (Pubitemid 29415520)
65. Stat3 contributes to keloid pathogenesis via promoting collagen production, cell proliferation and migration. Lim CP, Phan TT, Lim IJ, Cao X, Oncogene 2006 25 39 5416 5425 10.1038/sj.onc.1209531 16619044 (Pubitemid 44330284)
66. Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. Ng DC, Lin BH, Lim CP, Huang G, Zhang T, Poli V, Cao X, J Cell Biol 2006 172 2 245 257 10.1083/jcb.200503021 16401721 (Pubitemid 43112971)
67. Mapping the chromosomal targets of STAT1 by Sequence Tag Analysis of Genomic Enrichment (STAGE). Bhinge AA, Kim J, Euskirchen GM, Snyder M, Iyer VR, Genome Res 2007 17 6 910 916 10.1101/gr.5574907 17568006 (Pubitemid 46919725)
68. Stat1-independent induction of SOCS-3 by interferon-gamma is mediated by sustained activation of Stat3 in mouse embryonic fibroblasts. Ramana CV, Kumar A, Enelow R, Biochem Biophys Res Commun 2005 327 3 727 733 10.1016/j.bbrc.2004. 12.074 15649407 (Pubitemid 40092810)